{
    "root": "31696241-ba81-9128-e063-6294a90a069a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Atorvastatin Calcium",
    "value": "20250328",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "SODIUM CARBONATE",
            "code": "45P3261C7T"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ARGININE",
            "code": "94ZLA3W45F"
        },
        {
            "name": "ATORVASTATIN CALCIUM TRIHYDRATE",
            "code": "48A5M73Z4Q"
        }
    ],
    "indications": "Atorvastatin calcium tablets are indicated:\n                  \n                     To reduce the risk of:\n  \n   \n                           Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD\n                           MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD\n                           Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD\n                        \n                     \n                     As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:\n  \n   \n                           Adults with primary hyperlipidemia.\n                           Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                        \n                     \n                     As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).\n                     As an adjunct to diet for the treatment of adults with:\n  \n   \n                           Primary dysbetalipoproteinemia\n                           Hypertriglyceridemia",
    "contraindications": "Take orally once daily with or without food ( 2.1 ). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating atorvastatin calcium tablets, and adjust dosage if necessary ( 2.1 ). Adults ( 2.2 ): Recommended starting dosage is 10 or 20 mg once daily; dosage range is 10 mg to 80 mg once daily. Patients requiring LDL-C reduction > 45% may start at 40 mg once daily. Pediatric Patients Aged 10 Years of Age and Older with HeFH : Recommended starting dosage is 10 mg once daily; dosage range is 10 to 20 mg once daily ( 2.3 ). Pediatric Patients Aged 10 Years of Age and Older with HoFH : Recommended starting dosage is 10 to 20 mg once daily; dosage range is 10 to 80 mg once daily ( 2.4 ). See full prescribing information for atorvastatin calcium tablet dosage modifications due to drug interactions ( 2.5 ).",
    "warningsAndPrecautions": "Atorvastatin Calcium Tablets, USP are available containing atorvastatin calcium, USP equivalent to 10 mg, 20 mg, 40 mg or 80 mg of atorvastatin.\n                  The 10 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with\n \n  10on one side of the tablet and blank on the other side. They are available as follows:\n\n \n                  NDC 51079-208-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each).\n                  The 20 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with\n \n  20on one side of the tablet and blank on the other side. They are available as follows:\n\n \n                  NDC 51079-209-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each).\n                  The 40 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with\n \n  40on one side of the tablet and blank on the other side. They are available as follows:\n\n \n                  NDC 51079-210-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each).\n                  The 80 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with\n \n  80on one side of the tablet and blank on the other side. They are available as follows:\n\n \n                  NDC 51079-211-03 – Unit dose blister packages of 30 (5 cards of 6 tablets each).\n                  \n                     Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]",
    "adverseReactions": "Acute liver failure or decompensated cirrhosis\n  \n   [see\n   \n    Warnings and Precautions (5.3)]\n  \n   \n                     \n                     Hypersensitivity to atorvastatin or any excipients in atorvastatin calcium tablets. Hypersensitivity reactions, including anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported\n  \n   [see\n   \n    Adverse Reactions (6.2)]\n  \n   ."
}